메뉴 건너뛰기




Volumn 10, Issue 12, 2010, Pages 1491-1495

Immunotherapy of type 1 diabetes - How to rationally prioritize combination therapies in T1D

Author keywords

Combination therapy; Immunotherapy; Type 1 diabetes

Indexed keywords

CD3 ANTIBODY; DACLIZUMAB; EPIDERMAL GROWTH FACTOR; GASTRIN; GLUTAMATE DECARBOXYLASE 65; INSULIN; LANSOPRAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; SITAGLIPTIN; THYMOCYTE ANTIBODY;

EID: 78649983200     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2010.07.008     Document Type: Article
Times cited : (23)

References (39)
  • 1
    • 43649106996 scopus 로고    scopus 로고
    • Extreme genetic risk for type 1A diabetes in the post-genome era
    • E.E. Baschal, and G.S. Eisenbarth Extreme genetic risk for type 1A diabetes in the post-genome era J Autoimmun 31 1 2008 1 6
    • (2008) J Autoimmun , vol.31 , Issue.1 , pp. 1-6
    • Baschal, E.E.1    Eisenbarth, G.S.2
  • 2
    • 36448978896 scopus 로고    scopus 로고
    • Type 1 diabetes as a relapsing-remitting disease?
    • M. von Herrath, S. Sanda, and K. Herold Type 1 diabetes as a relapsing-remitting disease? Nat Rev Immunol 7 12 2007 988 994
    • (2007) Nat Rev Immunol , vol.7 , Issue.12 , pp. 988-994
    • Von Herrath, M.1    Sanda, S.2    Herold, K.3
  • 3
    • 67650999438 scopus 로고    scopus 로고
    • Immunoregulatory mechanisms triggered by viral infections protect from type 1 diabetes in mice
    • C.M. Filippi Immunoregulatory mechanisms triggered by viral infections protect from type 1 diabetes in mice J Clin Invest 119 6 2009 1515 1523
    • (2009) J Clin Invest , vol.119 , Issue.6 , pp. 1515-1523
    • Filippi, C.M.1
  • 4
    • 58149337282 scopus 로고    scopus 로고
    • Viral trigger for type 1 diabetes: Pros and cons
    • C.M. Filippi, and M.G. von Herrath Viral trigger for type 1 diabetes: pros and cons Diabetes 57 11 2008 2863 2871
    • (2008) Diabetes , vol.57 , Issue.11 , pp. 2863-2871
    • Filippi, C.M.1    Von Herrath, M.G.2
  • 5
    • 70349673424 scopus 로고    scopus 로고
    • Immunotherapy for the prevention and treatment of type 1 diabetes: Human trials and a look into the future
    • M. Rewers, and P. Gottlieb Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future Diab Care 32 10 2009 1769 1782
    • (2009) Diab Care , vol.32 , Issue.10 , pp. 1769-1782
    • Rewers, M.1    Gottlieb, P.2
  • 6
    • 70349705744 scopus 로고    scopus 로고
    • Immunotherapy for the prevention and treatment of type 1 diabetes: Optimizing the path from bench to bedside
    • D. Bresson, and M. von Herrath Immunotherapy for the prevention and treatment of type 1 diabetes: optimizing the path from bench to bedside Diab Care 32 10 2009 1753 1768
    • (2009) Diab Care , vol.32 , Issue.10 , pp. 1753-1768
    • Bresson, D.1    Von Herrath, M.2
  • 7
    • 34848887156 scopus 로고    scopus 로고
    • Recovery from diabetes in mice by beta cell regeneration
    • T. Nir, D.A. Melton, and Y. Dor Recovery from diabetes in mice by beta cell regeneration J Clin Invest 117 9 2007 2553 2561
    • (2007) J Clin Invest , vol.117 , Issue.9 , pp. 2553-2561
    • Nir, T.1    Melton, D.A.2    Dor, Y.3
  • 8
    • 0029826977 scopus 로고    scopus 로고
    • B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: Analysis of a new "speed congenic" stock of NOD.Ig mu null mice
    • D.V. Serreze B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig mu null mice J Exp Med 184 5 1996 2049 2053
    • (1996) J Exp Med , vol.184 , Issue.5 , pp. 2049-2053
    • Serreze, D.V.1
  • 9
    • 70449480577 scopus 로고    scopus 로고
    • Rituximab, B-lymphocyte depletion, and preservation of beta-cell function
    • M.D. Pescovitz Rituximab, B-lymphocyte depletion, and preservation of beta-cell function N Engl J Med 361 22 2009 2143 2152
    • (2009) N Engl J Med , vol.361 , Issue.22 , pp. 2143-2152
    • Pescovitz, M.D.1
  • 10
    • 0027958044 scopus 로고
    • Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice
    • L. Chatenoud Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice Proc Natl Acad Sci USA 91 1 1994 123 127
    • (1994) Proc Natl Acad Sci USA , vol.91 , Issue.1 , pp. 123-127
    • Chatenoud, L.1
  • 11
    • 0037198420 scopus 로고    scopus 로고
    • Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
    • K.C. Herold Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus N Engl J Med 346 22 2002 1692 1698
    • (2002) N Engl J Med , vol.346 , Issue.22 , pp. 1692-1698
    • Herold, K.C.1
  • 12
    • 20044375937 scopus 로고    scopus 로고
    • A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes
    • K.C. Herold A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes Diabetes 54 6 2005 1763 1769
    • (2005) Diabetes , vol.54 , Issue.6 , pp. 1763-1769
    • Herold, K.C.1
  • 14
    • 34547230077 scopus 로고    scopus 로고
    • CD3-specific antibodies: A portal to the treatment of autoimmunity
    • L. Chatenoud, and J.A. Bluestone CD3-specific antibodies: a portal to the treatment of autoimmunity Nat Rev Immunol 7 8 2007 622 632
    • (2007) Nat Rev Immunol , vol.7 , Issue.8 , pp. 622-632
    • Chatenoud, L.1    Bluestone, J.A.2
  • 15
    • 85056050903 scopus 로고    scopus 로고
    • Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset
    • F. Saudek Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset Rev Diabet Stud 1 2 2004 80 88
    • (2004) Rev Diabet Stud , vol.1 , Issue.2 , pp. 80-88
    • Saudek, F.1
  • 16
    • 0028331371 scopus 로고
    • Effect of adjuvant therapy on development of diabetes in mouse and man
    • N. Shehadeh Effect of adjuvant therapy on development of diabetes in mouse and man Lancet 343 8899 1994 706 707
    • (1994) Lancet , vol.343 , Issue.8899 , pp. 706-707
    • Shehadeh, N.1
  • 17
    • 51649084550 scopus 로고    scopus 로고
    • Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism
    • L. Ban Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism Proc Natl Acad Sci USA 105 36 2008 13644 13649
    • (2008) Proc Natl Acad Sci USA , vol.105 , Issue.36 , pp. 13644-13649
    • Ban, L.1
  • 18
    • 67650079482 scopus 로고    scopus 로고
    • Etanercept treatment in children with new-onset type 1 diabetes: Pilot randomized, placebo-controlled, double-blind study
    • L. Mastrandrea Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study Diab Care 32 7 2009 1244 1249
    • (2009) Diab Care , vol.32 , Issue.7 , pp. 1244-1249
    • Mastrandrea, L.1
  • 19
    • 0032146564 scopus 로고    scopus 로고
    • IL-1 produced and released endogenously within human islets inhibits beta cell function
    • M. Arnush IL-1 produced and released endogenously within human islets inhibits beta cell function J Clin Invest 102 3 1998 516 526
    • (1998) J Clin Invest , vol.102 , Issue.3 , pp. 516-526
    • Arnush, M.1
  • 20
    • 34247170807 scopus 로고    scopus 로고
    • Interleukin-1-receptor antagonist in type 2 diabetes mellitus
    • C.M. Larsen Interleukin-1-receptor antagonist in type 2 diabetes mellitus N Engl J Med 356 15 2007 1517 1526
    • (2007) N Engl J Med , vol.356 , Issue.15 , pp. 1517-1526
    • Larsen, C.M.1
  • 21
    • 78650033950 scopus 로고    scopus 로고
    • T.128. Short-term administration of anakinra does not appear to affect stimulated C-peptide responses acutely in patients with type 1 diabetes
    • S. Sanda T.128. Short-term administration of anakinra does not appear to affect stimulated C-peptide responses acutely in patients with type 1 diabetes Clin Immunol 131 Supplement 1 2009 S89
    • (2009) Clin Immunol , vol.131 , Issue.SUPPL. 1 , pp. 89
    • Sanda, S.1
  • 22
    • 58849117178 scopus 로고    scopus 로고
    • Improved efficacy of a tolerizing DNA vaccine for reversal of hyperglycemia through enhancement of gene expression and localization to intracellular sites
    • N. Solvason Improved efficacy of a tolerizing DNA vaccine for reversal of hyperglycemia through enhancement of gene expression and localization to intracellular sites J Immunol 181 12 2008 8298 8307
    • (2008) J Immunol , vol.181 , Issue.12 , pp. 8298-8307
    • Solvason, N.1
  • 23
    • 0031985550 scopus 로고    scopus 로고
    • Protection against autoimmune diabetes with oral insulin is associated with the presence of IL-4 type 2 T-cells in the pancreas and pancreatic lymph nodes
    • C. Ploix Protection against autoimmune diabetes with oral insulin is associated with the presence of IL-4 type 2 T-cells in the pancreas and pancreatic lymph nodes Diabetes 47 1 1998 39 44
    • (1998) Diabetes , vol.47 , Issue.1 , pp. 39-44
    • Ploix, C.1
  • 24
    • 0030754787 scopus 로고    scopus 로고
    • Metabolically inactive insulin analog prevents type i diabetes in prediabetic NOD mice
    • D.G. Karounos, J.S. Bryson, and D.A. Cohen Metabolically inactive insulin analog prevents type I diabetes in prediabetic NOD mice J Clin Invest 100 6 1997 1344 1348
    • (1997) J Clin Invest , vol.100 , Issue.6 , pp. 1344-1348
    • Karounos, D.G.1    Bryson, J.S.2    Cohen, D.A.3
  • 25
    • 33644856659 scopus 로고    scopus 로고
    • Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope
    • D.G. Alleva Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope Scand J Immunol 63 1 2006 59 69
    • (2006) Scand J Immunol , vol.63 , Issue.1 , pp. 59-69
    • Alleva, D.G.1
  • 26
    • 58149302798 scopus 로고    scopus 로고
    • Proinsulin peptide immunotherapy in type 1 diabetes: Report of a first-in-man phase i safety study
    • S.L. Thrower Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man phase I safety study Clin Exp Immunol 155 2 2009 156 165
    • (2009) Clin Exp Immunol , vol.155 , Issue.2 , pp. 156-165
    • Thrower, S.L.1
  • 27
    • 55249110198 scopus 로고    scopus 로고
    • GAD treatment and insulin secretion in recent-onset type 1 diabetes
    • J. Ludvigsson GAD treatment and insulin secretion in recent-onset type 1 diabetes N Engl J Med 359 18 2008 1909 1920
    • (2008) N Engl J Med , vol.359 , Issue.18 , pp. 1909-1920
    • Ludvigsson, J.1
  • 28
    • 25444455671 scopus 로고    scopus 로고
    • Regulation of pancreatic beta-cell mass
    • L. Bouwens, and I. Rooman Regulation of pancreatic beta-cell mass Physiol Rev 85 4 2005 1255 1270
    • (2005) Physiol Rev , vol.85 , Issue.4 , pp. 1255-1270
    • Bouwens, L.1    Rooman, I.2
  • 29
    • 35448986170 scopus 로고    scopus 로고
    • The replication of beta cells in normal physiology, in disease and for therapy
    • P.C. Butler The replication of beta cells in normal physiology, in disease and for therapy Nat Clin Pract Endocrinol Metab 3 11 2007 758 768
    • (2007) Nat Clin Pract Endocrinol Metab , vol.3 , Issue.11 , pp. 758-768
    • Butler, P.C.1
  • 30
    • 0033513455 scopus 로고    scopus 로고
    • Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats
    • G. Xu Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats Diabetes 48 12 1999 2270 2276
    • (1999) Diabetes , vol.48 , Issue.12 , pp. 2270-2276
    • Xu, G.1
  • 31
    • 0038497464 scopus 로고    scopus 로고
    • Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes
    • O.G. Kolterman Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes J Clin Endocrinol Metab 88 7 2003 3082 3089
    • (2003) J Clin Endocrinol Metab , vol.88 , Issue.7 , pp. 3082-3089
    • Kolterman, O.G.1
  • 32
    • 70349645780 scopus 로고    scopus 로고
    • Current advances and travails in islet transplantation
    • D.M. Harlan Current advances and travails in islet transplantation Diabetes 58 10 2009 2175 2184
    • (2009) Diabetes , vol.58 , Issue.10 , pp. 2175-2184
    • Harlan, D.M.1
  • 33
    • 65549128625 scopus 로고    scopus 로고
    • Human beta-cell precursors mature into functional insulin-producing cells in an immunoisolation device: Implications for diabetes cell therapies
    • S.H. Lee Human beta-cell precursors mature into functional insulin-producing cells in an immunoisolation device: implications for diabetes cell therapies Transplantation 87 7 2009 983 991
    • (2009) Transplantation , vol.87 , Issue.7 , pp. 983-991
    • Lee, S.H.1
  • 34
    • 67651064939 scopus 로고    scopus 로고
    • Real-time bioluminescence imaging of macroencapsulated fibroblasts reveals allograft protection in rhesus monkeys (Macaca mulatta)
    • A.F. Tarantal, C.C. Lee, and P. Itkin-Ansari Real-time bioluminescence imaging of macroencapsulated fibroblasts reveals allograft protection in rhesus monkeys (Macaca mulatta) Transplantation 88 1 2009 38 41
    • (2009) Transplantation , vol.88 , Issue.1 , pp. 38-41
    • Tarantal, A.F.1    Lee, C.C.2    Itkin-Ansari, P.3
  • 35
    • 22844439662 scopus 로고    scopus 로고
    • Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis
    • B.K. Kleinschmidt-DeMasters, and K.L. Tyler Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis N Engl J Med 353 4 2005 369 374
    • (2005) N Engl J Med , vol.353 , Issue.4 , pp. 369-374
    • Kleinschmidt-Demasters, B.K.1    Tyler, K.L.2
  • 36
    • 72249103423 scopus 로고    scopus 로고
    • Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes
    • K.I. Rother Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes Diab Care 32 12 2009 2251 2257
    • (2009) Diab Care , vol.32 , Issue.12 , pp. 2251-2257
    • Rother, K.I.1
  • 37
    • 77950651774 scopus 로고    scopus 로고
    • Genetic-induced variations in the GAD65 T-cell repertoire governs efficacy of anti-CD3/GAD65 combination therapy in new-onset type 1 diabetes
    • D. Bresson Genetic-induced variations in the GAD65 T-cell repertoire governs efficacy of anti-CD3/GAD65 combination therapy in new-onset type 1 diabetes Mol Ther 2009
    • (2009) Mol Ther
    • Bresson, D.1
  • 38
    • 33646392755 scopus 로고    scopus 로고
    • Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs
    • D. Bresson Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs J Clin Invest 116 5 2006 1371 1381
    • (2006) J Clin Invest , vol.116 , Issue.5 , pp. 1371-1381
    • Bresson, D.1
  • 39
    • 35548999311 scopus 로고    scopus 로고
    • Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells
    • N.A. Sherry Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells Endocrinology 148 11 2007 5136 5144
    • (2007) Endocrinology , vol.148 , Issue.11 , pp. 5136-5144
    • Sherry, N.A.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.